NewLink Genetics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch NLNK and buy or sell other stocks, ETFs, and their options commission-free!

About NLNK

Lumos Pharma, Inc. is a late-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of novel immunotherapeutic products to improve cancer treatment options for patients and physicians. 

CEO
Richard J. Hawkins
CEORichard J. Hawkins
Employees
Employees
Headquarters
Austin, Texas
HeadquartersAustin, Texas
Founded
1999
Founded1999
Employees
Employees

NLNK Key Statistics

Market cap
37.54M
Market cap37.54M
Price-Earnings ratio
-1.01
Price-Earnings ratio-1.01
Dividend yield
Dividend yield
Average volume
74.85K
Average volume74.85K
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$4.58
52 Week high$4.58
52 Week low
$1.37
52 Week low$1.37

Stock Snapshot

NewLink Genetics(NLNK) stock is priced at $3.01, giving the company a market capitalization of 37.54M. It carries a P/E multiple of -1.01.

NewLink Genetics(NLNK) stock opened on 2026-03-13 at —. The price climbed to — and dipped to —.

NewLink Genetics(NLNK) shares are trading with a volume of 0, against a daily average of 74.85K.

During the past year, NewLink Genetics(NLNK) stock moved between $1.37 at its lowest and $4.58 at its peak.

During the past year, NewLink Genetics(NLNK) stock moved between $1.37 at its lowest and $4.58 at its peak.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.